Baird reiterates its Outperform rating and $27 price target on Millennium Pharmaceuticals (Nasdaq: MLNM).

Following Millennium's update at an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE